MDT-AP-2382
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 49.800000000000004
- os_event
- false
- age_years
- 11.6
- sex
- M
- new_clusters
- C2
- umap1_2d
- 2.112825949
- umap2_2d
- -0.096098155
- umap1_3d
- -0.994859784
- umap2_3d
- -1.979673787
- umap3_3d
- -0.377328425
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.420
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.360
- KRAS_SIGNALING_DN+0.310
- ANGIOGENESIS+0.280
- OXIDATIVE_PHOSPHORYLATION+0.250
- MYOGENESIS+0.240
- IL6_JAK_STAT3_SIGNALING+0.230
- COAGULATION+0.220
- UV_RESPONSE_UP+0.210
- P53_PATHWAY+0.190
Top 10 suppressed
- PROTEIN_SECRETION-0.360
- MITOTIC_SPINDLE-0.320
- UV_RESPONSE_DN-0.320
- HEDGEHOG_SIGNALING-0.220
- ANDROGEN_RESPONSE-0.200
- PI3K_AKT_MTOR_SIGNALING-0.170
- INTERFERON_GAMMA_RESPONSE-0.110
- INTERFERON_ALPHA_RESPONSE-0.080
- BILE_ACID_METABOLISM-0.070
- PEROXISOME-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A409-01A-11R-A24H-07 | — | E | 0.790 |
| 2 | 9a4f9e4a-dc97-4f8d-9075-537b62fb98d3 | — | — | 0.777 |
| 3 | TCGA-60-2720-01A-01R-0851-07 | — | cohortSQ1 | 0.764 |
| 4 | 7dab0af8-ab64-4014-b7b7-bf0df59a1b3a | — | — | 0.755 |
| 5 | SJEPD001538_R1.RNA-Seq | EPN | Posterior Fossa EPN | 0.754 |
| 6 | MNG413 | — | — | 0.753 |
| 7 | R111 | — | — | 0.746 |
| 8 | X3a5c813b.6c47.49aa.916c.bcddbafdd54b | — | cohortA1 | 0.739 |
| 9 | TCGA-BA-6872-01A-11R-1873-07 | — | — | 0.734 |
| 10 | TCGA-XF-A9SU-01A-31R-A39I-07 | — | — | 0.724 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.420 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.360 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.310 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.280 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| COAGULATION | 0.220 | Binimetinib | — uncovered |
| UV_RESPONSE_UP | 0.210 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.190 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.170 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.170 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.160 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.150 | Cobimetinib | — uncovered |